TRVN OTC

Trevena, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing innovative pharmaceutical solutions for individuals suffering from central nervous system disorders. Its pipeline features several promising drug candidates: OLINVYK (Oliceridine) injection: A G protein-biased mu-opioid receptor (MOR) ligand engineered to manage acute pain ranging from moderate to severe. TRV027: Aimed at addressing acute lung injury, which contributes to acute respiratory distress syndrome (ARDS) and abnormal blood clotting in patients with COVID-19. TRV250: A G protein-biased delta-opioid receptor agonist under development for the treatment of acute migraine. TRV734: A small molecule G protein-biased MOR ligand designed for the management of both moderate-to-severe acute and chronic pain. TRV045: An innovative S1P modulator focused on providing relief for chronic pain. The company has also established a partnership with Imperial College London to investigate TRV027's potential in patients afflicted with COVID-19. Trevena, Inc., founded in 2007, operates from its headquarters in Chesterbrook, Pennsylvania.